Valeant's stock dropped in the last month on short-term profit taking. Xifaxan, B+L products and SILIQ are a few key products for successful turnaround. Fair value in the mid-$20. The weekly dip of around 10 percent in shares of Valeant
The complaint, filed in US District Court for the District of New Jersey, seeks to get compensation for a group of …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has begun a turnaround. The Laval, Canada-based drug manufacturer is on a growth path again after VRX stock came crashing from lofty highs. A new CEO now works to drive profits and reduce …
enabling it to focus its attention and resources on the transformation of Valeant. …
The defenses available to the targets of hostile takeovers are considerable and Valeant has now lost three hostile bids for public companies since 2011. Meanwhile, Allergan’s stock price nearly doubled over the past year without so much as …
Dec 21 (Reuters) - A U.S. judge has ruled that former Valeant Pharmaceuticals International Inc Chief Executive Officer Michael Pearson must pursue his claim that the drugmaker owes him more than 3 million shares with an arbitrator …
Investors in Valeant Pharmaceuticals International, Inc. VRX need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 8, 2017 $12 Call had some of the highest implied volatility of all …
Shares of Valeant Pharmaceuticals VRX surged more than 2% higher on Wednesday morning, touching a new 52-week high in the process. The embattled pharma stock continues to polarize investors, but its recent recovery is starting to …
Yahoo!2mon